Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.
Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.
Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.
Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL
Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.
Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.
Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.
Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL
Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.
Multidisciplinary experts discuss the diagnosis and management of haemophagocytic lymphohistiocytosis (HLH)
Learn about investigational protein degradation and immunomodulatory therapies in multiple myeloma.
Watch haemato-oncology experts discuss updates in managing R/R mantle cell lymphoma with CAR T-cell therapy.
Watch haemato-oncology experts discuss updates in R/R follicular lymphoma, with a focus on CAR T-cell therapy.
Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.
touchHAEMATOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events
Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.
Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).
Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.
Dr David Sallman reviews advances in HR-MDS management, including the mode of action and latest clinical data for emerging treatments.
Watch three experts discuss the pathophysiology of cold agglutinin disease (CAD) and the steps needed for an accurate diagnosis. The panel goes on to discuss how emerging treatment options are changing the management of patients with primary CAD and the importance of tailoring treatment to improve outcomes. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.
Three international experts discuss how novel agents approved for early lines of therapy are changing the landscape of RRMM treatment.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.